2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Diane Michele Provencher, MD

Chief of Division
Centre Hospitalier de l’Université de Montréal
1560 East Sherbrooke Est
Montreal, QC
Canada H2L 4M1

Papers:
8 A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)